13 results on '"Waldstreicher, Joanne"'
Search Results
2. Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies.
- Author
-
Caplan, Arthur L., Waldstreicher, Joanne, Childers, Karla, and Maree, Aran
- Subjects
- *
COVID-19 , *COVID-19 treatment , *PHARMACEUTICAL industry , *DRUGS - Abstract
In the quest to provide treatment for COVID-19 patients, available therapies that have been approved for other indications but have insufficient evidence of safety and efficacy for use against COVID-19 have been considered. One of the unintended consequences of this approach is the potential creation of shortages, depriving existing patients who are benefiting from products based on their proven indications. Here, a pharmaceutical company outlines their ethical decision-making framework to guide decision-making and ensure equity of access to products. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. The Yale Open Data Access (YODA) Project--A Mechanism for Data Sharing.
- Author
-
Krumholz, Harlan M. and Waldstreicher, Joanne
- Subjects
- *
DATA analysis , *SHARING , *COOPERATION , *INTERGROUP relations , *CLINICAL trials , *NEWSLETTERS , *COMMUNICATION , *MEDICAL research , *PUBLISHING , *STANDARDS - Abstract
As medical research moves toward the more open approach to data sharing from which physics, astronomy, and genetics currently benefit, the YODA Project offers one of several pioneering data-sharing mechanisms that are already in use. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Managing Conflicts of Interest in Industry-Sponsored Clinical Research: More Physician Engagement Is Required.
- Author
-
Waldstreicher, Joanne and Johns, Michael E.
- Subjects
- *
CONFLICT of interests , *PHYSICIANS , *CLINICAL trials , *MEDICAL research , *TRUST , *PHYSICIAN-patient relations , *MEDICAL equipment , *ATTITUDE (Psychology) , *FINANCE , *MEDICAL research laws , *OCCUPATIONAL roles , *PHYSICIAN engagement , *ENDOWMENT of research , *MEDICAL protocols , *PATIENT safety ,PATIENT Protection & Affordable Care Act - Abstract
The article discusses the authors' claim that additional physician engagement is required in order to manage conflicts of interest (COIs) involving industry-sponsored clinical research in America, and it mentions how real and perceived COIs can impact patient and physician trust in the research and development of drugs and medical devices. The U.S. Bayh-Dole Act and the Pharmaceutical Research and Manufacturers of America (PhRMA) group's Principles on Conduct of Clinical Trials are assessed.
- Published
- 2017
- Full Text
- View/download PDF
5. Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.
- Author
-
Narayanasamy, Shanti, Curtis, Lesley H, Hernandez, Adrian F, Woods, Christopher W, Moody, M Anthony, Sulkowski, Mark, Turbett, Sarah E, Baden, Lindsey R, Gulick, Roy M, Pau, Alice K, Adam, Stacey J, Marks, Peter, Stockbridge, Norman L, Dobbins, John R, Krofah, Esther, Leav, Brett, Pang, Phil, Roessig, Lothar, Vedin, Ola, and Waldstreicher, Joanne
- Subjects
- *
COVID-19 , *PATIENT advocacy , *INDUSTRIES , *PUBLIC health , *GOVERNMENT policy , *COVID-19 pandemic - Abstract
While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches to prepare for the next pandemic. In May 2022, the Duke Clinical Research Institute convened a think tank with thought leaders from academia, clinical practice, the pharmaceutical industry, patient advocacy, the National Institutes of Health, the US Food and Drug Administration, and the Centers for Disease Control and Prevention to share, firsthand, expert knowledge of the insights gained from the COVID-19 pandemic and how this acquired knowledge can help inform the next pandemic response. The think tank focused on pandemic preparedness, therapeutics, vaccines, and challenges related to clinical trial design and scale-up during the early phase of a pandemic. Based on the multi-faceted discussions, we outline 10 key steps to an improved and equitable pandemic response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.
- Author
-
Marquis-Gravel, Guillaume, Roe, Matthew T., Turakhia, Mintu P., Boden, William, Temple, Robert, Sharma, Abhinav, Hirshberg, Boaz, Slater, Paul, Craft, Noah, Stockbridge, Norman, McDowell, Bryan, Waldstreicher, Joanne, Bourla, Ariel, Bansilal, Sameer, Wong, Jennifer L., Meunier, Claire, Kassahun, Helina, Coran, Philip, Bataille, Lauren, and Patrick-Lake, Bray
- Subjects
- *
CLINICAL trials , *ELECTRONIC health records , *WEARABLE technology , *MOBILE apps , *PILOT projects - Abstract
The complexity and costs associated with traditional randomized, controlled trials have increased exponentially over time, and now threaten to stifle the development of new drugs and devices. Nevertheless, the growing use of electronic health records, mobile applications, and wearable devices offers significant promise for transforming clinical trials, making them more pragmatic and efficient. However, many challenges must be overcome before these innovations can be implemented routinely in randomized, controlled trial operations. In October of 2018, a diverse stakeholder group convened in Washington, DC, to examine how electronic health record, mobile, and wearable technologies could be applied to clinical trials. The group specifically examined how these technologies might streamline the execution of clinical trial components, delineated innovative trial designs facilitated by technological developments, identified barriers to implementation, and determined the optimal frameworks needed for regulatory oversight. The group concluded that the application of novel technologies to clinical trials provided enormous potential, yet these changes needed to be iterative and facilitated by continuous learning and pilot studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Data Acquisition, Curation, and Use for a Continuously Learning Health System.
- Author
-
Krumholz, Harlan M., Terry, Sharon F., and Waldstreicher, Joanne
- Subjects
- *
HEALTH care reform , *HEALTH information exchanges , *HEALTH information services , *INFORMATION sharing , *ACCESS to information - Abstract
The article discusses the notion of a learning health system. Topics include the role of data acquisition and curation in health systems, impediments to the sharing of health data, and the selection of data-sharing tools and platforms that encourage the sharing of health information throughout a healthcare system.
- Published
- 2016
- Full Text
- View/download PDF
8. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia
- Author
-
Lowe, Franklin C., McConnell, John D., Hudson, Perry B., Romas, Nicholas A., Boake, Rex, Lieber, Michael, Elhilali, Mostafa, Geller, Jack, Imperto-McGinely, Juliane, Andriole, Gerald L., Bruskewitz, Reginald C., Walsh, Patrick C., Bartsch, Georg, Nacey, John N., Shah, Sukrut, Pappas, Frances, Ko, Amy, Cook, Thomas, Stoner, Elizabeth, and Waldstreicher, Joanne
- Subjects
- *
PROSTATE hypertrophy , *FINASTERIDE - Abstract
: ObjectivesTo summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important.: MethodsThe North American and International Phase III Finasteride trials enrolled symptomatic men with enlarged prostate glands. The initial 1-year placebo-controlled study was followed by a 5-year open-label extension. In total, 6-year finasteride data were available in 487 patients originally randomized to finasteride, and 5-year data were available on 238 patients originally randomized to placebo.: ResultsAfter 6 years of treatment with finasteride 5 mg, the mean quasi-American Urological Association Symptom Score improved by 4.0 points, the median prostate volume decreased by 24%, and the mean maximal urinary flow rate increased by 2.9 mL/s (P <0.001 for all parameters). Long-term finasteride treatment was well tolerated, with a low incidence of drug-related sexual adverse events occurring during the first year and even fewer occurrences during the 5-year open extension.: ConclusionsTreatment with finasteride leads to durable improvement in urinary tract symptoms, flow rate, and prostate volume, with no increase in the prevalence of drug-related adverse events over time. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
9. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia
- Author
-
Wessells, Hunter, Roy, Johnny, Bannow, John, Grayhack, John, Matsumoto, Alvin M., Tenover, Lisa, Herlihy, Richard, Fitch, William, Labasky, Richard, Auerbach, Stephen, Parra, Raul, Rajfer, Jacob, Culbertson, Jennifer, Lee, Michael, Bach, Mark A., Waldstreicher, Joanne, and PLESS Study Group
- Subjects
- *
HYPERPLASIA , *PLACEBOS - Abstract
: ObjectivesTo evaluate the incidence and resolution of sexual adverse experiences (AEs) in men with benign prostatic hyperplasia treated with finasteride 5 mg compared with placebo.: MethodsThe Proscar Long-term Efficacy and Safety Study (PLESS) was a 4-year, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of finasteride 5 mg in 3040 men, aged 45 to 78 years, with symptomatic benign prostatic hyperplasia, enlarged prostates, and no evidence of prostate cancer. Patients completed a questionnaire at screening regarding their history of sexual dysfunction. During treatment, spontaneously self-reported sexual AEs were recorded.: ResultsAt screening, 46% of patients in each treatment group reported some history of sexual dysfunction. During year 1 of the study, 15% of finasteride-treated patients and 7% of placebo-treated patients had sexual AEs that were considered drug related by the investigator (P <0.001). During years 2 to 4, no between-group difference was noted in the incidence of new sexual AEs (7% in each group). The drug-related sexual AE profile for finasteride was similar for men with or without a history of sexual dysfunction. Sexual AEs resolved while continuing therapy in 12% of finasteride patients and 19% of placebo patients. Only 4% of finasteride and 2% of placebo patients discontinued the study because of sexual AEs. In men who discontinued with a sexual AE, 50% and 41% experienced resolution of their sexual AE after discontinuing finasteride or placebo therapy, respectively.: ConclusionsCompared with placebo, men treated with finasteride experienced new drug-related sexual AEs with an increased incidence only during the first year of therapy. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
10. Storage (Irritative) and Voiding (Obstructive) Symptoms as Predictors of Benign Prostatic Hyperplasia Progression and Related Outcomes
- Author
-
Roehrborn, Claus G., McConnell, John D., Saltzman, Brian, Bergner, Donald, Gray, Todd, Narayan, Perinchery, Cook, Thomas J., Johnson-Levonas, Amy O., Quezada, Wilson A., and Waldstreicher, Joanne
- Subjects
- *
URINATION disorders , *PROSTATE hypertrophy , *PROSTATE surgery , *FINASTERIDE , *URINARY tract infections - Abstract
Objectives: To assess the utility of voiding and filling symptom subscores in predicting features of benign prostatic hyperplasia (BPH) progression, including acute urinary retention (AUR) and prostate surgery.Methods: The Proscar Long-term Efficacy and Safety Study (PLESS) was a 4-year study designed to evaluate the effects of finasteride versus placebo in men with lower urinary tract symptoms (LUTS), clinical evidence of BPH, and no evidence of prostate cancer. A self-administered questionnaire was employed to quantify LUTS at baseline. Receiver operating characteristics (ROC) curves were used to assess baseline characteristics from patients treated with placebo as predictors of outcomes. The characteristics assessed included the overall symptom score (Quasi-AUA SI), separate voiding and filling subscores, prostate volume (PV) and serum prostate-specific antigen (PSA) levels.Results: PV and PSA were superior to the symptom scores at predicting episodes of spontaneous AUR and all types of AUR. The Quasi-AUA SI and the filling and voiding subscores were effective at predicting progression to surgery; however, PSA was more effective at predicting this outcome. To better evaluate symptoms as predictors of surgery, patients who experienced a preceding episode of AUR were excluded from the surgery analysis. In the absence of preceding AUR, the best predictors of future surgery were the Quasi-AUA SI and the filling subscore.Conclusions: Among men with LUTS, clinical BPH and no history of AUR, the overall symptom score and storage subscore are useful parameters to aid clinicians in identifying patients at risk for future prostate surgery. PV and PSA were the best predictors of AUR, while PSA was the best predictor of prostate surgery (for all indications). [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
11. Patient-Perceived Importance of Negative Effects of Androgenetic Alopecia in Women.
- Author
-
Girman, Cynthia J., Hartmaier, Susan, Roberts, Janet, Bergfeld, Wilma, and Waldstreicher, Joanne
- Subjects
- *
BALDNESS , *ANDROGENS , *PSYCHOLOGY of women , *WOMEN'S health , *PATIENTS , *QUALITY of life , *PATIENT satisfaction - Abstract
The article presents a study, which investigated patient perception of the importance of negative effects of androgenetic alopecia (AGA) in women. Despite the prevalence of AGA and the acceptance of its associated psychological factors in women, few studies have directly queried women about which specific aspects of their lives are affected by hair thinning and the relative importance of such effects. Perceptions of such negative effects can influence patient satisfaction, health-related quality of life and the impetus to seek medical attention for hair loss. Most of the literature about the psychosocial impact of AGA has focused on men. The hair loss pattern in women typically differs from that found in men and is characterized by diffuse decrease in the density of the hair over the top of the scalp. In addition, the psychosocial impact of AGA may be more pronounced in women than in men, partially because of societal pressure for physical attractiveness, the greater psychological investment of women in their appearance, and the lower prevalence in women and, hence, the impression of deviating from normal.
- Published
- 1999
- Full Text
- View/download PDF
12. Lowering LDL cholesterol with simvastatin, an HMG-CoA reductase inhibitor, does not affect luteal function in women
- Author
-
Santoro, Nanette, Plotkin, Diane, Mitchel, Yale, Waldstreicher, Joanne, and Liu, Minzhi
- Published
- 2002
- Full Text
- View/download PDF
13. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia.
- Author
-
McConnell, John D., Bruskewitz, Reginald, Walsh, Patrick, Andriole, Gerald, Lieber, Michael, Holtgrewe, H. Logan, Albertsen, Peter, Roehrborn, Claus G., Nickel, J. Curtis, Wang, Daniel Z., Taylor, Alice M., and Waldstreicher, Joanne
- Subjects
- *
FINASTERIDE , *BENIGN prostatic hyperplasia , *THERAPEUTICS - Abstract
Background: Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, are not known. Methods: In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. Results: During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P<0.001). Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001). Conclusions: Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the probability of surgery and acute urinary retention. (N Engl J Med 1998;338:557-63.) [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.